CDK1 and cancer: This increase of CDK1 activity was only observed 72 h after treatment with gemcitabine/Abraxane in tumors formed by fl-CCs co-injected with mt-e-CAFs (Fig. 8b (ii)), revealing a delay of cancer cell response to chemotherapy in the presence of mt-e-CAFs in live tumors.